-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Exploring the challenges, impacts and implications of risk-based monitoring
Richard C Zink
Commentary: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Geographic distribution of clinical trials may lead to inequities in access
Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Research Article: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
Walter J Urba, Brendan D Curti
Editorial: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation
-
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Marinus W Lobbezoo, A Hilary Calvert, Elizabeth A Eisenhauer,Giuseppe Giaccone
Research Update: Clinical Investigation